**Long term results of down-staging and liver transplantation for patients with hepatocellular carcinoma beyond the conventional criteria**

Matteo Ravaioli1, Federica Odaldi1, Alessandro Cucchetti1, Franco Trevisani2, Fabio Piscaglia3, Vanessa De Pace1, Valentina Rosa Bertuzzo1, Flavia Neri1, Rita Golfieri4, Alberta Capelli4, Antonietta D’Errico5, Matteo Cescon1, Massimo Del Gaudio1, Guido Fallani1, Antonio Siniscalchi6, Maria Cristina Morelli1, Francesca Ciccarese7, Maria Di Marco8, Fabio Farinati9, Edoardo Giovanni Giannini10, Antonio Daniele Pinna1.

1 Department of General Surgery and Transplantation, S. Orsola - Malpighi Hospital, University of Bologna, Bologna, Italy.

2 Department of Medical and Surgical Sciences, Semeiotica Medica Unit, S. Orsola - Malpighi Hospital, University of Bologna, Bologna, Italy.

3 Division of Internal Medicine, Department of Digestive Disease and Internal Medicine, S. Orsola -Malpighi Hospital, University of Bologna, Bologna, Italy.

4 Department of Digestive Disease and Internal Medicine, Radiology Unit, S. Orsola - Malpighi Hospital, Bologna, University of Bologna, Bologna, Italy.

5 Department of Specialised, Experimental and Diagnostic Medicine, Pathology Unit, S. Orsola -Malpighi Hospital, University of Bologna, Bologna, Italy.

6 Department of Anesthesia and Intensive Care, Division of Anesthesiology, S. Orsola - Malpighi Hospital, University of Bologna, Bologna, Italy.

7 Division of Surgery, Policlinico San Marco, Zingonia, Ostio Sotto, Bergamo, Italy

8 Division of Medicine, Ospedale Bolognini, Seriate, Bergamo, Italy.

9 Department of Surgery and Gastroenterological Sciences, University of Padova, Padova, Italy.

10 Department of Internal Medicine, Gastroenterology Unit, IRCCS - Azienda Ospedaliera Universitaria San Martino, Genova, Italy.

**Supplemental Information**

*Table:* Demographical, cancer, anti-tumoral treatment and survival data of HCC liver recipients.

|  |  |
| --- | --- |
| Variable | N = 535 |
| Age (year) | 66 (60 – 70) |
| Male | 420 (78.5%) |
| MELD at diagnosis | 10 (8 – 13) |
| AFP (ng/mL) | 23.2 (6.6 – 202) |
| Number of lesions | 2 (1 – 4) |
| Single tumor | 259 (48.4%) |
| 2-3 tumors | 58 (10.8%) |
| More than 3 tumors | 218 (40.7%) |
| Maximum tumor diameter | 4.2 (3.0 – 6.5) |
| Treatment adopted |  |
| TACE/TAE | 273 (51.1%) |
| BSC / Other | 93 (17.3%) |
| Ablation | 69 (12.9%) |
| HR | 80 (14.9%) |
| Sorafenib | 20 (3.8%) |
| Overall survival |  |
| Median (months; 95% C.I.) | 23.1 (20.6 – 25.7) |
| 1-year | 73.6% |
| 3-year | 34.2% |
| 5-year | 18.1% |

ITA.LI.CA. population. Values are reported as median and interquartile range.